Developmental Clinical Studies:To determine the effectiveness of kisspeptin to induce oocyte maturation in IVF treatment

体外受精（IVF）治疗广泛且成功地用于治疗不孕症，但可能导致称为卵巢过度刺激综合征（OHSS）的危及生命的疾病。轻度OHSS发生在所有IVF周期的约1/3中，而中度或重度OHSS发生在IVF周期的1/10中。原因是在试管婴儿治疗中使用了一种药物，这种药物过于强烈地刺激生殖激素的释放。Kisspeptin是一种天然存在于男性和女性体内的激素，它刺激生殖激素分泌，类似于正常月经周期女性的刺激。在这项研究中，我们将了解Kisspeptin在需要IVF治疗的患者中的有效性。最终，我们研究的目的将是确定在IVF治疗中使用kisspeptin是否可以预防健康的不孕症妇女发生OHSS的潜在生命威胁风险。

In vitro fertilisation (IVF) treatment is widely and successfully used to treat infertility, but can cause the life threatening condition called ovarian hyperstimulation syndrome (OHSS). Mild forms of OHSS occur in approximately 1/3rd of all IVF cycles, whilst moderate or severe OHSS occurs in up to 1/10th of IVF cycles. The cause is the use of a drug in IVF treatment which too powerfully stimulates the release of reproductive hormones. Kisspeptin is a hormone found naturally in men and women and it stimulates reproductive hormone secretion similarly to the stimulation which occurs in women with a normal menstrual cycle. In this study we will find out how effective kisspeptin is in patients requiring IVF treatment. Ultimately the aim of our research will be to determine if the use of kisspeptin in IVF treatment could prevent the potentially life threatening risk of OHSS in women with infertility who are otherwise healthy.